Botez M I, Botez-Marquard T, Elie R, Le Marec N, Pedraza O L, Lalonde R
Centre Hospitalier de l'Université de Montréal - Campus Hôtel-Dieu, Service de Neurologie, Unité de Neurologie du Comportement, Neurobiologie et Neuropsychologie, Montreal, Qué., Canada.
Eur Neurol. 1999;41(4):212-5. doi: 10.1159/000008053.
The efficacy of amantadine, a dopamine-releasing agent and antagonist of the N-methyl-D-aspartate glutamate receptor, was evaluated in patients with olivopontocerebellar atrophy. By contrast to an untreated control group whose terminal performance deteriorated on 8 of 8 measurements of reaction time and movement time, patients treated with amantadine for a mean duration of over 40 months had improved performances in 1 of 4 reaction time measurements and in 3 of 4 movement time measurements and remained stable on the others. These results demonstrate long-term benefits of amantadine in olivopontocerebellar atrophy-induced deficits of movement initiation and movement completion.
金刚烷胺是一种多巴胺释放剂和N-甲基-D-天冬氨酸谷氨酸受体拮抗剂，研究人员评估了其对橄榄体脑桥小脑萎缩患者的疗效。与未治疗的对照组相比，该对照组在8次反应时间和运动时间测量中有8次最终表现恶化，而接受金刚烷胺治疗平均超过40个月的患者，在4次反应时间测量中有1次表现改善，在4次运动时间测量中有3次表现改善，其他测量结果保持稳定。这些结果表明，金刚烷胺对橄榄体脑桥小脑萎缩引起的运动启动和运动完成缺陷具有长期益处。
Zotero 插件